Skip to content

BCBS Alabama

Does BCBS Alabama cover Wegovy?

Yes. BCBS Alabama covers Wegovy for weight loss with prior authorization if your BMI is 30 or higher, or 27 or higher with a related condition. Other policy requirements and your plan's benefits also apply.

Policy document

  • Employer and ACA Marketplace: Covered with requirements. See the qualification pathways below.

Earliest policy review June 2, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Weight Loss (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Adult obesity

All of:

  • Age ≥ 18 years
  • BMI ≥ 30 kg/m2 (or ≥ 23 kg/m2 for South Asian, Southeast Asian, East Asian adults)

Adult overweight with comorbidity

All of:

  • Age ≥ 18 years
  • BMI ≥ 27 kg/m2 (or ≥ 23 kg/m2 for South Asian, Southeast Asian, East Asian adults)

Plus any one of:

  • Hypertension
  • Type 2 diabetes
  • Dyslipidemia
  • OSA
  • CVD
  • MASH
  • other weight-related comorbidity

Pediatric obesity (age 12+)

All of:

  • Age ≥ 12 years
  • BMI ≥ 95th percentile for age/sex OR ≥ 30 kg/m2 (whichever is lower)

Documentation to bring

  • Baseline BMI documentation meeting threshold (≥ 30 kg/m2, or ≥ 27 kg/m2 with comorbidity, or ≥ 23 kg/m2 for qualifying Asian ethnicities)
  • Documentation of qualifying weight-related comorbidity if BMI 27–29.9 kg/m2
  • For pediatric patients: documentation of BMI ≥ 95th percentile for age/sex
  • Documentation of reduced calorie diet and increased physical activity as adjunct

Approval and renewal

  • Renewal: At least 5% weight loss after 12 weeks at a therapeutic dose is required for continuation. Policy states efficacy should be assessed after 12 weeks at therapeutic dose.
  • Renewal: At least 12 weeks on therapy before the first renewal.

Not covered when

  • Concomitant use with other semaglutide-containing products not recommended
  • Concomitant use with any other GLP-1 receptor agonist not recommended
  • Pregnancy

Policy note: Policy covers both Wegovy subcutaneous injection and Wegovy tablet (oral semaglutide) formulations. Wegovy HD (higher-dose subcutaneous) is listed separately in FDA table but shares the same weight loss indication. Pediatric coverage (age ≥ 12) is noted in FDA labeling for subcutaneous injection. The 5% weight loss threshold at 12 weeks is cited from guidelines as the efficacy assessment standard.

Policy effective April 20, 2026 · verified June 2, 2026 · source: Albp Weight Management Paql Prog Sum · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Heart Disease Risk Reduction (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

CV risk reduction in adults with established CVD and overweight/obesity without diabetes

All of:

  • Age ≥ 45 years
  • Established cardiovascular disease
  • BMI ≥ 27 kg/m2
  • No diabetes diagnosis (SELECT trial enrolled patients without diabetes)

Plus any one of:

  • History of non-fatal MI
  • History of non-fatal stroke
  • Other established CV disease

Documentation to bring

  • Documentation of established cardiovascular disease (CV death history, non-fatal MI, non-fatal stroke, or equivalent)
  • Baseline BMI documentation ≥ 27 kg/m2
  • Confirmation of absence of diabetes diagnosis
  • Age ≥ 45 years confirmed

Not covered when

  • Patients WITH diabetes were excluded from the SELECT trial; CV indication inferred for non-diabetic patients only
  • Concomitant use with other semaglutide-containing products not recommended
  • Concomitant use with any other GLP-1 receptor agonist not recommended
  • Pregnancy

Policy note: CV risk reduction indication supported by SELECT trial data (NCT03574597): semaglutide 2.4 mg reduced MACE by 20% vs placebo in patients ≥ 45 years with BMI ≥ 27 and established CVD WITHOUT diabetes. The policy document references this trial to support the indication. Age minimum of 45 is derived from SELECT trial enrollment criteria referenced in the document. The FDA label indication is for adults with established CV disease and obesity or overweight, but the document specifically references the non-diabetic population from SELECT.

Policy effective April 20, 2026 · verified June 2, 2026 · source: Albp Weight Management Paql Prog Sum · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Liver Disease (MASH) (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Noncirrhotic MASH with moderate-to-advanced fibrosis (F2-F3)

All of:

  • Adult patient (≥ 18 years)
  • Diagnosis of noncirrhotic MASH (formerly NASH)
  • Fibrosis stage F2 or F3 confirmed by non-invasive testing or biopsy
  • No cirrhosis

Plus any one of:

  • FIB-4 score indicating moderate/high risk (< 1.30 low risk; 1.30–2.67 indeterminate; > 2.67 high risk) with confirmatory testing as needed
  • VCTE/FibroScan elastography confirming F2-F3 fibrosis
  • MRE confirming F2-F3 fibrosis
  • ELF test result indicating significant fibrosis
  • Liver biopsy confirming MASH with F2-F3 fibrosis

Documentation to bring

  • Diagnosis of noncirrhotic MASH (formerly NASH/MASLD)
  • Confirmation of fibrosis stage F2 or F3 via non-invasive testing (FIB-4, ELF, VCTE/FibroScan, or MRE) or liver biopsy
  • FIB-4 as primary risk stratification with secondary confirmatory elastography or ELF if FIB-4 is indeterminate
  • Confirmation of absence of cirrhosis

Not covered when

  • Cirrhotic MASH is excluded (FDA indication limited to noncirrhotic MASH)
  • Concomitant use with other semaglutide-containing products not recommended
  • Concomitant use with any other GLP-1 receptor agonist not recommended
  • Pregnancy

Policy note: FDA indication for MASH is limited to Wegovy subcutaneous injection (not the tablet formulation listed separately). Fibrosis stage F2-F3 required per both FDA label and the NASH trial (NCT04822181) referenced in the document. The document outlines a two-step non-invasive testing approach: Step 1 FIB-4 (low risk < 1.30, indeterminate 1.30–2.67, high risk > 2.67; for patients > 65 years, higher cutoff > 2.0 for rule-in), Step 2 ELF and/or elastography (VCTE) with specific cutpoints referenced (ELF < 7.7 low risk, 7.7–9.8 intermediate, ≥ 9.8 high risk; VCTE < 8 kPa low risk, 8–12 kPa indeterminate, > 12 kPa high risk/advanced fibrosis). MRE also noted as an option. Lookback periods for testing are not explicitly specified in the PA criteria section of this document. Alcohol abstinence recommended in advanced fibrosis but no specific gram limits stated as PA criteria. This is a Program Summary document; specific PA approval criteria thresholds may be in a separate criteria document.

Policy effective April 20, 2026 · verified June 2, 2026 · source: Albp Weight Management Paql Prog Sum · View policy document (PDF)

Open on its own page →

Questions people ask
Does BCBS Alabama cover Wegovy?
Yes. BCBS Alabama covers Wegovy for weight loss with prior authorization if your BMI is 30 or higher, or 27 or higher with a related condition. Other policy requirements and your plan's benefits also apply.
What does BCBS Alabama require to renew Wegovy?
Weight Loss — Applies to Employer and ACA Marketplace plans. At least 5% weight loss after 12 weeks at a therapeutic dose is required for continuation. Policy states efficacy should be assessed after 12 weeks at therapeutic dose. At least 12 weeks on therapy before the first renewal.
How current is this information?
The oldest review date among the policies on this page is June 2, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under BCBS Alabama: Mounjaro, Ozempic, Zepbound

Wegovy under other plans: Alabama Medicaid, BCBS Arizona, BCBS Arkansas, BCBS Louisiana, BCBS Massachusetts, BCBS Michigan, BCBS Minnesota, BCBS Nebraska

All insurance plans · All medications

Summary of BCBS Alabama's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.